Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) Price & Performance

Citius Pharmaceuticals IncTrade
iShares S&P GSCI Commodity-Indexed Trust ETFTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs iShares S&P GSCI Commodity-Indexed Trust ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while iShares S&P GSCI Commodity-Indexed Trust ETF trades at $32.61. The key difference: iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

CTXRGSG
Market Cap
$20.01M
Sector
HealthCommodities - Metals/Agriculture
52-Week High
$1.82$34.77
52-Week Low
$0.48$22.06
Enterprise Value
$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.

The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.

iShares S&P GSCI Commodity-Indexed Trust ETF

GSG trades at $32.65, up 1.02% today, with a bearish technical signal driven by moving averages. Recent news highlights its energy-centric commodity exposure, which fueled strong H1 2026 performance but faces volatility risks. Financial ratios are unavailable, limiting fundamental clarity.

Outlook is cautious due to sector volatility and geopolitical risks, with a recent downgrade to Hold. Opportunities lie in broad commodity exposure, but investors should weigh energy price swings and lack of current financial data against potential gains.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About iShares S&P GSCI Commodity-Indexed Trust ETF

GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.

Read more on GSG